Brought to you by 
Celgene licenses ABI009 to AADi LLC for oncology and cardio indications
16 Jan 2019
Executive Summary
Celgene Corp. granted biotech start-up AADi LLC rights to its ABI009, a nanoparticle albumin-bound (nab) version of sirolimus (rapamycin).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene licenses ABI009 to AADi LLC for oncology and cardio indications
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice